CA2384812A1 - Method and compositions for inhibiting adhesion formation - Google Patents

Method and compositions for inhibiting adhesion formation Download PDF

Info

Publication number
CA2384812A1
CA2384812A1 CA002384812A CA2384812A CA2384812A1 CA 2384812 A1 CA2384812 A1 CA 2384812A1 CA 002384812 A CA002384812 A CA 002384812A CA 2384812 A CA2384812 A CA 2384812A CA 2384812 A1 CA2384812 A1 CA 2384812A1
Authority
CA
Canada
Prior art keywords
accordance
antagonist molecule
monoclonal antibody
composition
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002384812A
Other languages
English (en)
French (fr)
Inventor
David A. Cheresh
Bruce Lessey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Scripps Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2384812A1 publication Critical patent/CA2384812A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/045—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002384812A 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation Abandoned CA2384812A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40552299A 1999-09-23 1999-09-23
US09/405,522 1999-09-23
PCT/US2000/026095 WO2001021196A1 (en) 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation

Publications (1)

Publication Number Publication Date
CA2384812A1 true CA2384812A1 (en) 2001-03-29

Family

ID=23604048

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002384812A Abandoned CA2384812A1 (en) 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation

Country Status (9)

Country Link
EP (1) EP1223962A4 (cg-RX-API-DMAC7.html)
JP (1) JP2003509468A (cg-RX-API-DMAC7.html)
KR (1) KR20020048941A (cg-RX-API-DMAC7.html)
CN (1) CN1399554A (cg-RX-API-DMAC7.html)
AU (1) AU781442B2 (cg-RX-API-DMAC7.html)
BR (1) BR0014222A (cg-RX-API-DMAC7.html)
CA (1) CA2384812A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02003079A (cg-RX-API-DMAC7.html)
WO (1) WO2001021196A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2025685T3 (da) 2007-08-15 2013-09-02 Canadian Blood Services Monoklonale antistoffer mod BETA3-integriner.
CA3030111C (en) 2016-07-13 2025-07-08 Mochida Pharmaceutical Co., Ltd. COMPOUND PREVENTING ADHESION
CN111936175A (zh) * 2018-01-15 2020-11-13 持田制药株式会社 防粘连用组合物
KR102318958B1 (ko) * 2019-08-08 2021-10-27 고려대학교 산학협력단 인테그린 α2β1 억제제를 유효성분으로 포함하는 조직 유착 예방 또는 치료용 약제학적 조성물
WO2021202643A1 (en) * 2020-03-31 2021-10-07 The Regents Of The University Of California Compositions and methods for treating dysregulated wound healing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
AU8918898A (en) * 1997-08-25 1999-03-16 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibi tors

Also Published As

Publication number Publication date
WO2001021196A1 (en) 2001-03-29
JP2003509468A (ja) 2003-03-11
AU7985000A (en) 2001-04-24
EP1223962A4 (en) 2004-01-21
BR0014222A (pt) 2003-02-25
AU781442B2 (en) 2005-05-26
MXPA02003079A (es) 2004-04-21
CN1399554A (zh) 2003-02-26
EP1223962A1 (en) 2002-07-24
KR20020048941A (ko) 2002-06-24

Similar Documents

Publication Publication Date Title
Verrando et al. Monoclonal antibody GB3, a new probe for the study of human basement membranes and hemidesmosomes
AU2016248341B2 (en) Bioconjugates and uses thereof
JP2744130B2 (ja) 敗血症治療用組成物
DE69034116T3 (de) Hemmung der anheftung von lymphozyten an das gefässendothelium mittels einer neuen extrazellulärer matrixrezeptor-ligand-wechselwirkung
Binnebösel et al. Morphology, quality, and composition in mature human peritoneal adhesions
CZ198497A3 (en) Cyclic peptides inhibiting fibronectin adhesion, process of their preparation and pharmaceutical compositions containing thereof
US11529424B2 (en) Synthetic bioconjugates
Kim et al. Differential expression of basement membrane collagen in membranous nephropathy
AU781442B2 (en) Method and compositions for inhibiting adhesion formation
Maldonado et al. Involvement of integrins with adhesion-promoting, heparin-binding peptides of type IV collagen in cultured human corneal epithelial cells.
JP3706151B2 (ja) トロンボスポンジン−様活性を有するペプチド及びその治療のための使用
US8680075B2 (en) Methods and compositions for inhibiting cellular proliferation and surgical adhesion
RU2152801C2 (ru) Антифибриновое антитело для применения в качестве противотромботического средства
EP3261672B1 (en) Molecules disrupting pyruvate kinase m2 and integrin interaction and uses thereof
JPH07502726A (ja) 抗−padgem抗体を用いる血管狭窄の抑制
AU1907800A (en) Modified antibodies and antibody fragments with increased duration of activity
JP2006522140A (ja) 線維症の治療用ポリマー薬剤
Tran et al. An in vivo evaluation of a chondroitin sulfate solution to prevent postoperative intraperitoneal adhesion formation
Ross et al. Fibrillin containing elastic microfibrils support platelet adhesion under dynamic shear conditions
Almeida et al. A novel lamina lucida component of epithelial and endothelial basement membranes detected by LH39 monoclonal antibody
Hirata et al. Immunohistological localization of the novel epitope related to type IV collagen in normal and diseased renal tissues
Ettinger Bladder reconstruction with amniochorion
HK1007683B (en) Treatment for inflammatory bowel disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead